Why Attend the 3rd Raw Materials for Cell & Gene Therapy Summit?
Move on from theory and step inside the conversations shaping how raw material strategies are implemented in practice. Across technical case studies, peer-led discussions, and interactive workshops, you’ll explore how teams are managing suppliers, qualifying materials, overseeing supply chains, and navigating regulatory uncertainty in real-world settings.
Designed to encourage open dialogue, this meeting creates space for candid, experience-driven exchange that dives in deep to create a one-stop-shop for everything you need to know about raw materials and everyone you need to meet.
Expect a highly collaborative environment where you can challenge assumptions, validate your approach, and leave better equipped to make confident raw material decisions for your program.
There’s Something for Everyone at the 3rd Raw Materials for Cell & Gene Therapy Summit
Shape Your End-to-End Raw Materials Strategy
Step back and assess the bigger picture with strategic sessions from Aspen Neuroscience, Genentech, and Fate Therapeutics, exploring how to build phase-appropriate raw material frameworks that support both development agility and long-term scale.
Technical Case Studies Across Modalities & Development Stages
Compare how Ray Therapeutics (AAV gene therapy), Cabaletta Bio (autologous cell therapy), and Tr1X Bio (allogeneic cell therapy) are tackling material qualification, variability, and purification challenges, and understand how strategies need to evolve from early development to commercial readiness.
Strengthen Supplier Engagement & Supply Chain Resilience
Hear from Bristol Myers Squibb and Kite Pharma on how to engage suppliers more strategically, qualify secondary sources, and protect continuity as programs move toward late-stage and commercial manufacturing.
Gain Clarity on Evolving Regulatory Expectations
Engage directly with the United States Pharmacopeia (USP) to understand how emerging standards and guidance are shaping raw material quality, risk assessment, and regulatory confidence for cell and gene therapies.
Attending Companies Include